Global Meningococcal Group A and C Conjugate Vaccine Market Growth 2026-2032

July 2026 | 82 pages | ID: G5603AB9D31FEN
LP Information

Abstracts

The global Meningococcal Group A and C Conjugate Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

United States market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Meningococcal Group A and C Conjugate Vaccine players cover Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the ?Meningococcal Group A and C Conjugate Vaccine Industry Forecast? looks at past sales and reviews total world Meningococcal Group A and C Conjugate Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Meningococcal Group A and C Conjugate Vaccine sales for 2026 through 2032. With Meningococcal Group A and C Conjugate Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Group A and C Conjugate Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Meningococcal Group A and C Conjugate Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Group A and C Conjugate Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Meningococcal Group A and C Conjugate Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Group A and C Conjugate Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Group A and C Conjugate Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Group A and C Conjugate Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Prefilled
• Non-prefilled

Segmentation by Application:

• Adults
• Children

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Sanofi Pasteur
• GSK
• Pfizer
• Chongqing Zhifei Biological Products

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Meningococcal Group A and C Conjugate Vaccine market?
• What factors are driving Meningococcal Group A and C Conjugate Vaccine market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Meningococcal Group A and C Conjugate Vaccine market opportunities vary by end market size?
• How does Meningococcal Group A and C Conjugate Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Meningococcal Group A and C Conjugate Vaccine Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Meningococcal Group A and C Conjugate Vaccine by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Meningococcal Group A and C Conjugate Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Meningococcal Group A and C Conjugate Vaccine Segment by Type
  2.2.1 Prefilled
  2.2.2 Non-prefilled
  2.2.3 Meningococcal Group A and C Conjugate Vaccine Sales by Type
    2.2.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
    2.2.3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue and Market Share by Type (2021-2026)
    2.2.3.3 Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Type (2021-2026)
2.3 Meningococcal Group A and C Conjugate Vaccine Segment by Application
  2.3.1 Adults
  2.3.2 Children
  2.3.3 Meningococcal Group A and C Conjugate Vaccine Sales by Application
    2.3.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sale Market Share by Application (2021-2026)
    2.3.3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue and Market Share by Application (2021-2026)
    2.3.3.3 Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Meningococcal Group A and C Conjugate Vaccine Breakdown Data by Company
  3.1.1 Global Meningococcal Group A and C Conjugate Vaccine Annual Sales by Company (2021-2026)
  3.1.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Meningococcal Group A and C Conjugate Vaccine Annual Revenue by Company (2021-2026)
  3.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Company (2021-2026)
  3.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Group A and C Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Meningococcal Group A and C Conjugate Vaccine Product Location Distribution
  3.4.2 Players Meningococcal Group A and C Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL GROUP A AND C CONJUGATE VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Meningococcal Group A and C Conjugate Vaccine Market Size by Geographic Region (2021-2026)
  4.1.1 Global Meningococcal Group A and C Conjugate Vaccine Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Meningococcal Group A and C Conjugate Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Meningococcal Group A and C Conjugate Vaccine Market Size by Country/Region (2021-2026)
  4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Meningococcal Group A and C Conjugate Vaccine Sales Growth
4.4 APAC Meningococcal Group A and C Conjugate Vaccine Sales Growth
4.5 Europe Meningococcal Group A and C Conjugate Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Growth

5 AMERICAS

5.1 Americas Meningococcal Group A and C Conjugate Vaccine Sales by Country
  5.1.1 Americas Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026)
  5.1.2 Americas Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021-2026)
5.2 Americas Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026)
5.3 Americas Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Meningococcal Group A and C Conjugate Vaccine Sales by Region
  6.1.1 APAC Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2026)
  6.1.2 APAC Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021-2026)
6.2 APAC Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026)
6.3 APAC Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Meningococcal Group A and C Conjugate Vaccine by Country
  7.1.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026)
  7.1.2 Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021-2026)
7.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026)
7.3 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine by Country
  8.1.1 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Group A and C Conjugate Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Group A and C Conjugate Vaccine
10.4 Industry Chain Structure of Meningococcal Group A and C Conjugate Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Meningococcal Group A and C Conjugate Vaccine Distributors
11.3 Meningococcal Group A and C Conjugate Vaccine Customer

12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL GROUP A AND C CONJUGATE VACCINE BY GEOGRAPHIC REGION

12.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Region
  12.1.1 Global Meningococcal Group A and C Conjugate Vaccine Forecast by Region (2027-2032)
  12.1.2 Global Meningococcal Group A and C Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Meningococcal Group A and C Conjugate Vaccine Forecast by Type (2027-2032)
12.7 Global Meningococcal Group A and C Conjugate Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Sanofi Pasteur
  13.1.1 Sanofi Pasteur Company Information
  13.1.2 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
  13.1.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Sanofi Pasteur Main Business Overview
  13.1.5 Sanofi Pasteur Latest Developments
13.2 GSK
  13.2.1 GSK Company Information
  13.2.2 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
  13.2.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 GSK Main Business Overview
  13.2.5 GSK Latest Developments
13.3 Pfizer
  13.3.1 Pfizer Company Information
  13.3.2 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
  13.3.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Pfizer Main Business Overview
  13.3.5 Pfizer Latest Developments
13.4 Chongqing Zhifei Biological Products
  13.4.1 Chongqing Zhifei Biological Products Company Information
  13.4.2 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
  13.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Chongqing Zhifei Biological Products Main Business Overview
  13.4.5 Chongqing Zhifei Biological Products Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Meningococcal Group A and C Conjugate Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Meningococcal Group A and C Conjugate Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Prefilled
Table 4. Major Players of Non-prefilled
Table 5. Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Meningococcal Group A and C Conjugate Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global Meningococcal Group A and C Conjugate Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Meningococcal Group A and C Conjugate Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global Meningococcal Group A and C Conjugate Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Meningococcal Group A and C Conjugate Vaccine Producing Area Distribution and Sales Area
Table 21. Players Meningococcal Group A and C Conjugate Vaccine Products Offered
Table 22. Meningococcal Group A and C Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Meningococcal Group A and C Conjugate Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Meningococcal Group A and C Conjugate Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Meningococcal Group A and C Conjugate Vaccine
Table 52. Key Market Challenges & Risks of Meningococcal Group A and C Conjugate Vaccine
Table 53. Key Industry Trends of Meningococcal Group A and C Conjugate Vaccine
Table 54. Meningococcal Group A and C Conjugate Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Meningococcal Group A and C Conjugate Vaccine Distributors List
Table 57. Meningococcal Group A and C Conjugate Vaccine Customer List
Table 58. Global Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Meningococcal Group A and C Conjugate Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Meningococcal Group A and C Conjugate Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Meningococcal Group A and C Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Meningococcal Group A and C Conjugate Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Meningococcal Group A and C Conjugate Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Sanofi Pasteur Basic Information, Meningococcal Group A and C Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
Table 74. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Sanofi Pasteur Main Business
Table 76. Sanofi Pasteur Latest Developments
Table 77. GSK Basic Information, Meningococcal Group A and C Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
Table 79. GSK Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. GSK Main Business
Table 81. GSK Latest Developments
Table 82. Pfizer Basic Information, Meningococcal Group A and C Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
Table 84. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Chongqing Zhifei Biological Products Basic Information, Meningococcal Group A and C Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolios and Specifications
Table 89. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Chongqing Zhifei Biological Products Main Business
Table 91. Chongqing Zhifei Biological Products Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Meningococcal Group A and C Conjugate Vaccine
Figure 2. Meningococcal Group A and C Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Meningococcal Group A and C Conjugate Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Prefilled
Figure 12. Product Picture of Non-prefilled
Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type in 2026
Figure 14. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Meningococcal Group A and C Conjugate Vaccine Consumed in Adults
Figure 16. Global Meningococcal Group A and C Conjugate Vaccine Market: Adults (2021-2026) & (K Units)
Figure 17. Meningococcal Group A and C Conjugate Vaccine Consumed in Children
Figure 18. Global Meningococcal Group A and C Conjugate Vaccine Market: Children (2021-2026) & (K Units)
Figure 19. Global Meningococcal Group A and C Conjugate Vaccine Sale Market Share by Application (2025)
Figure 20. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application in 2026
Figure 21. Meningococcal Group A and C Conjugate Vaccine Sales by Company in 2026 (K Units)
Figure 22. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Company in 2026
Figure 23. Meningococcal Group A and C Conjugate Vaccine Revenue by Company in 2026 ($ millions)
Figure 24. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Company in 2026
Figure 25. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Meningococcal Group A and C Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 28. Americas Meningococcal Group A and C Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 29. APAC Meningococcal Group A and C Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 30. APAC Meningococcal Group A and C Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 31. Europe Meningococcal Group A and C Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 32. Europe Meningococcal Group A and C Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Americas Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country in 2026
Figure 36. Americas Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 37. Americas Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 38. Americas Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 39. United States Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region in 2026
Figure 44. APAC Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021-2026)
Figure 45. APAC Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 46. APAC Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 47. China Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. India Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country in 2026
Figure 55. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 56. Europe Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 57. Europe Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 58. Germany Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. France Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 66. Egypt Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Meningococcal Group A and C Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Meningococcal Group A and C Conjugate Vaccine in 2026
Figure 72. Manufacturing Process Analysis of Meningococcal Group A and C Conjugate Vaccine
Figure 73. Industry Chain Structure of Meningococcal Group A and C Conjugate Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Forecast by Region (2027-2032)
Figure 76. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share Forecast by Application (2027-2032)